Charles Schwab Investment Management Inc. Purchases 35,926 Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

Charles Schwab Investment Management Inc. raised its position in shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) by 3.3% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,139,252 shares of the biopharmaceutical company’s stock after purchasing an additional 35,926 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.55% of Sangamo Therapeutics worth $1,162,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. FMR LLC increased its stake in shares of Sangamo Therapeutics by 16.5% in the 3rd quarter. FMR LLC now owns 544,003 shares of the biopharmaceutical company’s stock worth $471,000 after purchasing an additional 77,032 shares in the last quarter. State Street Corp grew its stake in shares of Sangamo Therapeutics by 28.0% during the 3rd quarter. State Street Corp now owns 664,621 shares of the biopharmaceutical company’s stock valued at $576,000 after acquiring an additional 145,400 shares during the period. XTX Topco Ltd increased its holdings in Sangamo Therapeutics by 167.8% in the 3rd quarter. XTX Topco Ltd now owns 103,716 shares of the biopharmaceutical company’s stock worth $90,000 after acquiring an additional 64,981 shares in the last quarter. Geode Capital Management LLC raised its stake in Sangamo Therapeutics by 14.6% during the 3rd quarter. Geode Capital Management LLC now owns 2,138,309 shares of the biopharmaceutical company’s stock worth $1,853,000 after acquiring an additional 272,123 shares during the period. Finally, Virtu Financial LLC purchased a new position in Sangamo Therapeutics during the third quarter valued at approximately $150,000. Hedge funds and other institutional investors own 56.93% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently commented on SGMO. StockNews.com downgraded shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, December 24th. Truist Financial dropped their price objective on shares of Sangamo Therapeutics from $7.00 to $5.00 and set a “buy” rating for the company in a report on Thursday, January 23rd. Jefferies Financial Group reduced their target price on Sangamo Therapeutics from $7.00 to $3.00 and set a “buy” rating on the stock in a report on Tuesday, December 31st. Wells Fargo & Company dropped their price target on Sangamo Therapeutics from $3.00 to $2.00 and set an “equal weight” rating for the company in a research note on Tuesday, December 31st. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $2.00 price objective on shares of Sangamo Therapeutics in a research note on Tuesday, March 18th. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, Sangamo Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $5.17.

Sangamo Therapeutics Price Performance

Shares of SGMO opened at $0.82 on Monday. The firm has a market capitalization of $184.26 million, a price-to-earnings ratio of -1.09 and a beta of 1.49. The company has a 50-day moving average of $1.04 and a 200 day moving average of $1.41. Sangamo Therapeutics, Inc. has a 1-year low of $0.30 and a 1-year high of $3.18.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its quarterly earnings results on Monday, March 17th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.02). The firm had revenue of $7.55 million during the quarter, compared to analysts’ expectations of $11.70 million. Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%. On average, equities analysts anticipate that Sangamo Therapeutics, Inc. will post -0.46 earnings per share for the current fiscal year.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.